For people with diabetes and obesity, ozempic can reduce the risk of ten types of cancer, research suggests, reports The Daily Mail.

Under the study, researchers from Case Western Reserve University in Ohio tracked more than 1.6million patients who had type 2 diabetes, with an average age of 60, between 2005 and 2018. 

Over a follow-up of 15 years, they compared the cancer risk among patients on GLP-1 agonists against those on insulin as well another cohort of GLP-1 with a group on metformin, another diabetes medication. 

Those taking insulin were more than twice as likely to be diagnosed with pancreatic, colorectal, gallbladder and meningioma cancer in comparison,

Writing in the journal, JAMA Network Open, scientists said: 'Compared with insulins, GLP-1s were associated with a significantly lower risk of 10 of the 13 obesity associated cancers.' 

The biggest reduction was seen in gallbladder cancer, with patients on GLP-1 agonists having 65 percent less chance of having the disease than insulin patients. 

Other big reductions were seen for pancreatic cancer (59 percent), ovarian cancer (48 percent) and colorectal cancer (46 percent)..

However, results for thyroid cancer, however, showed “no statistically different risk.” 

Research in mice and rats has suggested jabs like Ozempic and Wegovy, which work by mimicking hormones, could raise the risk of medullary thyroid cancer (MTC).

'The findings from our study together with previous reports of insulins promoting cancer growth suggest that GLP-1s might be associated with increased risk of thyroid cancer,” the scientists said. 

However, they cautioned further research was necessary to confirm their findings.